MERTK as a novel therapeutic target in head and neck cancer

Although head and neck cancer (HNSCC) is the sixth most common tumor entity worldwide therapy options remain limited leading to 5-year survival rates of only 50 %. MERTK is a promising therapeutic target in several tumor entities, however, its role in HNSCC has not been described yet. The aim of our...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: von Mässenhausen, Anne, Sanders, Christine, Thewes, Britta, Deng, Mario, Queisser, Angela, Vogel, Wenzel, Kristiansen, Glen, Duensing, Stefan, Schröck, Andreas, Bootz, Friedrich, Brossart, Peter, Kirfel, Jutta, Heasley, Lynn, Brägelmann, Johannes, Perner, Sven
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078043/
https://ncbi.nlm.nih.gov/pubmed/27081701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8724
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars